EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) — Adamas Prescription drugs, Inc. (Nasdaq: ADMS) at the moment introduced that the compensation committee of the corporate’s board of administrators granted two new staff the choice to buy an mixture of 28,500 shares of the corporate’s widespread stock, at a per share train price of $4.88, the closing buying and selling price on December 7, and restricted stock items to amass 14,250 shares of the corporate’s widespread stock. The stock choices and restricted stock items vest over 4 years and have been granted pursuant to the Adamas Prescription drugs, Inc. 2016 Inducement Plan, which was permitted by the corporate’s board of administrators in March 2016 below Rule 5653(c)(4) of the Nasdaq World Marketplace for fairness grants to induce new staff to enter into employment with the corporate.
About Adamas Prescription drugs, Inc.
At Adamas our imaginative and prescient is obvious – to ship revolutionary medicines that scale back the burden of neurological ailments on sufferers, caregivers and society. We’re a totally built-in firm targeted on rising a portfolio of therapies to handle a variety of neurological ailments. For extra data, please go to www.adamaspharma.com.
Vice President, Communications & Engagement